ApplicationTampere, FinlandFounded 2025· One of 381 Application companies tracked by AMPulse
Develops a 4D bioprinting suite to produce biocompatible, full-thickness human corneas using iPSC-derived cells to address the global shortage of donor corneas.
(1) Claimed: Scalable GMP production of biocompatible corneas using 4D bioprinting. (2) Verified: €8M Horizon Europe grant approval and consortium of 9 specialized partners.
Differentiation
Value Proposition
Provides a sustainable, scalable alternative to donor corneas by producing functional grafts via 4D bioprinting, potentially reducing long-term costs associated with donor procurement and transplant waitlists.
How They Differentiate
Differentiates by focusing on full-thickness corneal grafts using 4D bioprinting and iPSC technology, whereas existing solutions often focus on partial layers or non-biological synthetic materials.
Market & Competition
Target Customers
Clinicians and hospitals specializing in corneal transplantation
Industry Verticals
Ophthalmology; Regenerative Medicine
Competitors
Precise Bio; Pandorum Technologies; LinkoCare Life Sciences
Growth & Milestones
Growth Metrics
Aims for scalable GMP production to treat millions; €8M grant funding secured for development.
Major Milestones
Horizon Europe grant approval; Consortium assembly; Project launch; Targeting pilot transplants in 3-5 years; Clinical availability targeted by 2035
Notable Customers
Tampere University; StemSight Oy; Brinter AM Technologies Oy; Maastricht University; University Hospital Cologne (Klinikum der Universität zu Köln); University of Helsinki; Cellbox Solutions; Asphalion SL; Crowdhelix Limited
KeratOPrinter is a research consortium developing a 4D bioprinting suite to produce full-thickness human corneas from induced pluripotent stem cell (iPSC)-derived cells. The project addresses the chronic global shortage of donor corneas by offering a scalable, sustainable alternative to cadaveric grafts. Unlike existing approaches that focus on partial corneal layers or synthetic materials, KeratOPrinter aims to fabricate complete, biocompatible grafts that integrate with host tissue.
The core technology combines material extrusion (MEX) bioprinting with time-responsive (4D) materials that change shape or function after implantation. The platform uses iPSC-derived corneal cells and proprietary bioinks, supported by AI-driven quality control. The consortium also develops portable incubators to support transport and storage of printed grafts. The goal is to establish good manufacturing practice (GMP) production of corneas that can be transplanted into patients.
Target customers are clinicians and hospitals specializing in corneal transplantation. The consortium includes nine partners: Tampere University, StemSight Oy, Brinter AM Technologies Oy, Maastricht University, University Hospital Cologne, University of Helsinki, Cellbox Solutions, Asphalion SL, and Crowdhelix Limited. The project is funded by an €8 million Horizon Europe grant and aims to begin pilot human transplants within three to five years, with clinical availability targeted by 2035.
KeratOPrinter competes with Precise Bio, Pandorum Technologies, and LinkoCare Life Sciences. Its differentiation lies in combining 4D bioprinting with iPSC technology to produce full-thickness grafts, rather than partial layers or non-biological synthetics. The consortium's academic and clinical depth provides a strong research foundation, but the long timeline to clinical use and the complexity of regulatory approval for a living, printed tissue product represent significant risks. The project is led by Professor Heli Skottman, an expert in regenerative medicine and ocular biology at Tampere University.
Competitive Intelligence
Competitors, SWOT analysis, and investment insights